Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

First Posted Date: 2004-09-14

Last Posted Date: 2013-07-10

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00004089

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

Phase 1

Completed

Conditions: Chronic Myeloproliferative Disorders
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous Condition
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Biological: recombinant interferon alfa
Biological: recombinant interleukin-12

First Posted Date: 2004-09-13

Last Posted Date: 2013-02-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00003451

Locations: 🇺🇸
Arthur G. James Cancer Hospital - Ohio State University, Columbus, Ohio, United States

Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Childhood Solid Tumor, Protocol Specific

Interventions: Biological: filgrastim
Drug: cyclophosphamide
Drug: tirapazamine

First Posted Date: 2004-09-13

Last Posted Date: 2013-02-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT00003288

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 25 locations

Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer

Phase 1

Terminated

Conditions: Kidney Neoplasms

First Posted Date: 2004-09-13

Last Posted Date: 2012-10-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 3

Registration Number: NCT00091611

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma (Skin)

First Posted Date: 2004-09-09

Last Posted Date: 2015-04-30

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT00091338

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer

Phase 2

Terminated

Conditions: Primary Peritoneal Cavity Cancer
Recurrent Ovarian Epithelial Cancer

Interventions: Drug: romidepsin

First Posted Date: 2004-09-09

Last Posted Date: 2013-03-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 51

Registration Number: NCT00091195

Locations: 🇺🇸
High Point Regional Hospital, High Point, North Carolina, United States
🇺🇸
Wake Forest University Health Sciences, Winston-Salem, North Carolina, United States

Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment

Phase 2

Completed

Conditions: Childhood Central Nervous System Germ Cell Tumor
Childhood Extragonadal Germ Cell Tumor
Childhood Hepatoblastoma
Childhood Hepatocellular Carcinoma
Childhood High-grade Cerebral Astrocytoma
Childhood Low-grade Cerebral Astrocytoma
Childhood Malignant Ovarian Germ Cell Tumor
Childhood Malignant Testicular Germ Cell Tumor
Childhood Teratoma
Recurrent Adrenocortical Carcinoma

Interventions: Drug: oxaliplatin

First Posted Date: 2004-09-09

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 180

Registration Number: NCT00091182

Locations: 🇺🇸
Children's Oncology Group, Arcadia, California, United States

Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage II Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Biological: cetuximab
Biological: bevacizumab
Drug: erlotinib hydrochloride

First Posted Date: 2004-09-08

Last Posted Date: 2014-05-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 143

Registration Number: NCT00091026

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

Phase 1

Completed

Conditions: Hepatic Complications
Malignant Neoplasm

Interventions: Drug: bortezomib
Other: pharmacological study

First Posted Date: 2004-09-08

Last Posted Date: 2013-12-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 80

Registration Number: NCT00091117

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸
Wayne State University, Detroit, Michigan, United States

Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery

Phase 2

Terminated

Conditions: Gastrointestinal Stromal Tumor

Interventions: Biological: oblimersen sodium
Drug: imatinib mesylate
Other: laboratory biomarker analysis

First Posted Date: 2004-09-08

Last Posted Date: 2013-06-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT00091078

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy